Search results
Results from the WOW.Com Content Network
Baclofen, sold under the brand name Lioresal among others, is a medication used to treat muscle spasticity such as from a spinal cord injury or multiple sclerosis. [8] [9] It may also be used for hiccups and muscle spasms near the end of life, [9] and off-label to treat alcohol use disorder [10] [11] or opioid withdrawal symptoms. [12]
CGP7930 was developed in Novartis and has been used extensively for scientific research. It has anxiolytic effects in animal studies, [ 6 ] [ 7 ] and has a synergistic effect with GABA B agonists such as baclofen and GHB , [ 8 ] [ 9 ] as well as reducing self-administration of alcoholic drinks and cocaine .
Spasticity is often treated with the drug baclofen, which acts as an agonist at GABA receptors, which are inhibitory. Spastic cerebral palsy is the most common form of cerebral palsy, which is a group of permanent movement problems that do not get worse over time. GABA's inhibitory actions contribute to baclofen's efficacy as an anti-spasticity ...
Arbaclofen placarbil (/ ɑːr ˈ b æ k l oʊ f ɛ n p l ə ˈ k ɑːr b ɪ l / ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen.Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels.
LTI-03 was generally well-tolerated, and there were no drug-related adverse events that resulted in a discontinuation of the trial. ... Price Action: ALRN stock is trading 5.48% lower at $3.62 at ...
BSPP is a compound used in scientific research which acts as a positive allosteric modulator at the GABA B receptor. [1] It has a synergistic effect with GABA B agonists such as baclofen at GABA B autoreceptors but not heteroreceptors, suggesting it may be useful for distinguishing between these GABA B receptor subtypes.
Researchers at the University of Colorado Anschutz Medical Campus received up to $46 million in a grant to help develop an innovative treatment to cure blindness.
Previous research published in the Journal of Public Health also found that adults age 50 and older had a 66% increased mortality risk within the first 90 days of becoming a widow or widower.